2023 Drug Approval Highlights

Last year, the FDA green-lit 34 new small molecule drugs, marking a year of significant breakthroughs in drug discovery. Watch this engaging Flash Talk where Dennis X. Hu, Lewis Pennington and Dennis Koester highlight the most exciting drug discovery stories and deep-dive into the most compelling case studies of small molecule drugs approved in 2023. This session explores innovative treatments across various disease areas, featuring drugs with fascinating target biology such as ritlecitinib, repotrectinib, omaveloxolone, and pirtobrutinib.

During this presentation, our team will provide insights into target rationale, hit finding strategies, lead optimization, and clinical differentiation. The team will highlight noteworthy aspects of each case study, sharing their perspectives on what makes these developments interesting.

00:00 Introduction
01:27 Presentation
03:03 Oncology small molecule drugs/Pirtobrutinib
10:09 Rare diseases
15:58 Infectious diseases
18:56 OB/Gyn
19:28 Dermatology
19:36 Endocrinology
20:53 Cardiology
21:31 Hematology
23:05 Diagnostic drugs
23:11 Neurology
24:40 Gastroenterology
25:25 Opthalmology
26:30 Ritlecitinib (case study)
39:35 Omaveloxolone (case study)
51:29 Repotrectinib (case study)
56:11 Pirtobrutinib (case study)
58:49 Other case studies on the Drug Hunter website
59:13 Q&A

Presented by Dennis Hu, CEO, Ph.D.; Dennis Koester, Ph.D., Director of Industry Research and Relations and Lew Pennington, Ph.D. Scientific Director

Recorded on Aug 1, 2024 as part of our Drug Hunter Flash Talk series.

For access to the full case studies mentioned in the presentation visit: https://drughunter.com/plans

Sign up for future sessions here: https://drughunter.com/flash-talk-ser...
Sign up for our free newsletter here: https://drughunter.com/newsletter-sig...